A detailed history of Redmile Group, LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Redmile Group, LLC holds 15,669,217 shares of ADCT stock, worth $30.7 Million. This represents 3.23% of its overall portfolio holdings.

Number of Shares
15,669,217
Previous 15,269,217 2.62%
Holding current value
$30.7 Million
Previous $48.3 Million 2.3%
% of portfolio
3.23%
Previous 3.15%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.59 - $4.01 $1.04 Million - $1.6 Million
400,000 Added 2.62%
15,669,217 $49.4 Million
Q1 2024

May 15, 2024

SELL
$1.66 - $5.29 $98,106 - $312,639
-59,100 Reduced 0.39%
15,269,217 $68.6 Million
Q4 2023

Feb 14, 2024

BUY
$0.47 - $1.79 $600,839 - $2.29 Million
1,278,382 Added 9.1%
15,328,317 $25.4 Million
Q2 2023

Aug 14, 2023

BUY
$1.9 - $2.66 $920,903 - $1.29 Million
484,686 Added 3.57%
14,049,935 $30.2 Million
Q1 2023

May 15, 2023

BUY
$1.92 - $5.45 $11.5 Million - $32.6 Million
5,974,400 Added 78.71%
13,565,249 $26.5 Million
Q4 2022

Feb 14, 2023

BUY
$2.87 - $5.24 $226,213 - $413,016
78,820 Added 1.05%
7,590,849 $29.1 Million
Q2 2022

Aug 15, 2022

BUY
$5.96 - $14.99 $474,416 - $1.19 Million
79,600 Added 1.07%
7,512,029 $59.7 Million
Q1 2022

May 16, 2022

SELL
$13.28 - $20.03 $247,008 - $372,558
-18,600 Reduced 0.25%
7,432,429 $109 Million
Q4 2021

Feb 14, 2022

SELL
$19.29 - $31.51 $1.51 Million - $2.47 Million
-78,300 Reduced 1.04%
7,451,029 $151 Million
Q3 2021

Nov 15, 2021

BUY
$20.45 - $30.0 $149,285 - $219,000
7,300 Added 0.1%
7,529,329 $204 Million
Q2 2021

Aug 16, 2021

BUY
$20.38 - $27.04 $4.35 Million - $5.78 Million
213,611 Added 2.92%
7,522,029 $183 Million
Q1 2021

May 17, 2021

BUY
$22.75 - $34.05 $12.5 Million - $18.7 Million
549,624 Added 8.13%
7,308,418 $178 Million
Q4 2020

Feb 16, 2021

BUY
$25.26 - $38.02 $10.2 Million - $15.4 Million
405,700 Added 6.39%
6,758,794 $216 Million
Q3 2020

Nov 16, 2020

BUY
$32.87 - $51.05 $27.2 Million - $42.2 Million
827,224 Added 14.97%
6,353,094 $210 Million
Q2 2020

Aug 14, 2020

BUY
$29.65 - $46.81 $164 Million - $259 Million
5,525,870 New
5,525,870 $259 Million

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $152M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.